Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

February was a turbulent month in general with the Russia-Ukraine situation taking most of the focus. BB Biotech, with its entire portfolio exposure in US and Western European biotechnology companies, is carefully monitoring implications from the geopolitical situation and its effect on the markets. Also, on a company-specific level our investments do not seem to be affected operationally by the situation in Russia and Ukraine. BB Biotech´s share price ended the month down by approximately 6%.

BB Biotech Update February 2022

February was a turbulent month in general with the Russia-Ukraine situation taking most of the focus. BB Biotech, with its entire portfolio exposure in US and Western European biotechnology companies, is carefully monitoring implications from the geopolitical situation and its effect on the markets. Also, on a company-specific level our investments do not seem to be affected operationally by the situation in Russia and Ukraine. BB Biotech´s share price ended the month down by approximately 6%.
09.03.2022 - BB Biotech